Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Vascular Ehlers-Danlos Syndrome

Open access
Frank, Michael, Adham, Salma, Seigle, Stéphanie, Legrand, Anne, Mirault, Tristan, Henneton, Pierrick, Albuisson, Juliette, Denarié, Nicolas, Mazzella, Jean-Michaël, Mousseaux, Elie, Messas, Emmanuel, Boutouyrie, Pierre, Jeunemaitre, Xavier·2019·Journal of the American College of Cardiology

Abstract

BACKGROUND Vascular Ehlers-Danlos syndrome (vEDS) is a rare genetic connective tissue disorder secondary to pathogenic variants within the COL3A1 gene, resulting in exceptional arterial and organ fragility and premature death. The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality. OBJECTIVES The authors herein describe the outcomes of a large cohort of vEDS patients followed ≤17 years in a single national referral center. METHODS All patients with molecularly confirmed vEDS were included in a retrospective cohort study. After an initial work-up, patients were treated or recommended for treatment with celiprolol (≤400 mg/day) in addition to usual care and scheduled for yearly follow-up. vEDS-related events and deaths were collected and recorded for each patient. RESULTS Between 2000 and 2017, 144 patients (median age at diagnosis 34.5 years, 91 probands) were included in this study. After a median follow-up of 5.3 years, overall patient survival was high (71.6%; 95% confidence interval: 50% to 90%) and dependent on the type of COL3A1 variant, age at diagnosis, and medical treatment. At the end of the study period, almost all patients (90.3%) were treated with celiprolol alone or in combination. More than two-thirds of patients remained clinically silent, despite a large number (51%) with previous arterial events or arterial lesions at molecular diagnosis. Patients treated with celiprolol had a better survival than others (p = 0.0004). The observed reduction in mortality was dose-dependent: the best protection was observed at the dose of 400 mg/day versus <400 mg/day (p = 0.003). During the period surveyed, the authors observed a statistically significant difference in the ratio of hospitalizations for acute arterial events/hospitalizations for regular follow-up before and after 2011. CONCLUSIONS In this long-term survey, vEDS patients exhibited a low annual occurrence of arterial complications and a high survival rate, on which the overall medical care seems to have a positive influence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2019.01.058

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 182

Metadata

Authors
Frank, M., Adham, S., Seigle, S., Legrand, A., Mirault, T., Henneton, P., Albuisson, J., Denarié, N., Mazzella, J.-M., Mousseaux, E., Messas, E., Boutouyrie, P., & Jeunemaitre, X.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2019-04
Volume
73
Issue
15
Pages
1948-1957
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2937445771
Cited by
182
References
7
FWCI
8.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vascular Ehlers-Danlos Syndrome. https://app.cochat.ai/papers/10.1016/j.jacc.2019.01.058
The paper
Frank, M., Adham, S., Seigle, S., Legrand, A., Mirault, T., Henneton, P., Albuisson, J., Denarié, N., Mazzella, J.-M., Mousseaux, E., Messas, E., Boutouyrie, P., & Jeunemaitre, X. (2019). Vascular Ehlers-Danlos Syndrome. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2019.01.058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.